Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
NantKwest is a biotechnology business based in the US. NantKwest stocks (NK.US) are listed on the NASDAQ and all prices are listed in US Dollars. NantKwest employs 171 staff and has a trailing 12-month revenue of around $111,000.
|Latest market close||$0.00|
|52-week range||$17.76 - $46.82|
|50-day moving average||$28.70|
|200-day moving average||$14.19|
|Wall St. target price||$18.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.89|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2022-01-18)||nan%|
|1 month (2021-12-25)||nan%|
|3 months (2021-10-29)||-100.00%|
|6 months (2021-07-29)||-100.00%|
|1 year (2021-01-29)||-100.00%|
|2 years (2020-01-29)||-100.00%|
|3 years (2019-01-29)||1.08|
|5 years (2017-01-27)||5.37|
Valuing NantKwest stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NantKwest's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NantKwest's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.56. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NantKwest's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Gross profit TTM||$111,000|
|Return on assets TTM||-36.2%|
|Return on equity TTM||-77.61%|
|Market capitalisation||$3.6 billion|
TTM: trailing 12 months
We're not expecting NantKwest to pay a dividend over the next 12 months.
NantKwest's shares were split on a 8:1 basis on 17 August 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 8 shares. This wouldn't directly have changed the overall worth of your NantKwest shares – just the quantity. However, indirectly, the new 87.5% lower share price could have impacted the market appetite for NantKwest shares which in turn could have impacted NantKwest's share price.
Over the last 12 months, NantKwest's shares have ranged in value from as little as $17.76 up to $46.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NantKwest's is 2.3862. This would suggest that NantKwest's shares are significantly more volatile than the average for this exchange and represent a higher risk.
NantKwest, Inc. , a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc.
Everything we know about the Nauticus Robotics, Inc. IPO, plus information on how to buy in.
What is Mogo and how can you access its new trading platform, MogoTrade? Find out in our review.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
This guide provides step-by-step instructions on how to buy Bitcoin Private, lists some exchanges where you can get it and provides daily price data on BTCP.
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Read our expert analysis on Kusama and how the token will perform in the future.
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.